LDS/Medical Tests/CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion), FISH, Bone Marrow

CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion), FISH, Bone Marrow

Fusion of the Fip1-like 1 (FIP1L1) gene to the PDGFRA gene generates a novel tyrosine kinase. This fusion was identified in half of the patients with hypereosiniphilic syndrome (HES) and results from a chromosomal deletion that includes the cysteine-rich hydrophobic domain 2 (CHIC2) locus at 4q12. FIP1L1-PDGFRA fusion is a continuously activated tyrosine kinase, and is a good therapeutic target candidate for imatinib in a group of HES patients. Idiopathic hypereosinophilic syndrome (HES) is characterized by unexplained, persistent elevated eosinophil count exhibiting abnormal eosinophil morphology and excessive secretion of eosinophilopoietic cytokines from a clonal population of lymphocytes. The etiology of HES is unknown; fusion event generating an abnormal and oncogenic tyrosine kinase (FIP1L1-PDGFRA) appears to be causative especially in males. Another disease affected by this fusion is mast cell disease (MCD). This clinically heterogeneous disorder is categorized to cutaneous and systemic (one or more extra-cutaneous organ involvement). Bothe disorders are treated with Imatinib mesylate drug. Imatinib mesylate is a small molecule tyrosine kinase inhibitor from the 2-phenylaminopyrimidine class of compounds, has shown activity in the treatment of malignancies that are associated with the constitutive activation of a specific subgroup of tyrosine kinases. FIP1L1-PDGFRA is a constitutively activated tyrosine kinase that transforms hematopoietic cells, and is a therapeutic target for imatinib in a subset of HES and MCD patients. Tricolor rearrangement probe set (FIP1L1, CHIC2, and PDGFRA) is hybridized to the samples and 200 interphase nuclei are analyzed.

  • This test provides genetic information for patients with hypereosinophilic syndrome (HES) and systemic mast cell disease (SMCD) involving CHIC2 deletion
  • This test helps to identify and track chromosome alterations and therapy response
  • Positive results reveal the presence of a neoplastic clone with the percent nuclei that have a deletion involving the CHIC2 gene region with retention of the FIP1L1/PDGFRA gene regions
  • This abnormality is usually associated with a chronic myeloproliferative disorder with associated eosinophilia. Patients with a CHIC2 deletion and FIP1L1/PDGFRA fusion reportedly respond to targeted therapy, such as imatinib mesylate

Negative; no changes in CHIC2, PDGFRA and FIP1L1 gene regions

Fluorescence In Situ Hybridization (FISH)

Blood (~10 mL) or bone marrow (2 mL) in tubes containing sodium heparin. Ambient temperature is the preferred storage condition.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
Bone marrow aspirate, CBC with differential, ova and parasite, IgE, Strongyloides Antibody, IgG.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login